Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT01772771
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Biospecimen Collection — PROCEDUREUndergo collection of blood, saliva/buccal swab samples
- Genetic Testing — OTHERCorrelative studies
- Medical Chart Review — OTHERReview of medical records
Study Details
This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.
Key Dates
- Start date
- Mar 1, 2012
- Status verified
- Feb 2026
- Primary completion
- Mar 1, 2032
- Completion
- Mar 1, 2033
Study Design
- Enrollment
- 12,000 participants (estimated)
Arms
- Arm: Ancillary-correlative (biospecimen collection, chart review)Patients' previously collected tissue samples are analyzed. Patients may also undergo collection of blood, saliva or buccal samples for analysis. Patients' medical records are reviewed.
Primary Outcome Measure
Frequency of mutations and co-mutations [ Time Frame: 20 years ]
Central Contacts
- Funda Meric-Bernstam, MD713-792-6940
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | Funda Meric-Bernstam 713-792-6940 Funda Meric-Bernstam (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By condition
By specialty
By research site
Related Studies
- Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton TherapyRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)PHASE1/PHASE2 · Recruiting · Plus Therapeutics · Manhasset, New York
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama